DEA Designates Naloxegol as Schedule II Drug

http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/dea-designates-naloxegol-schedule-ii-drug

The Drug Enforcement Agency (DEA) has designated naloxegol (Movantik) as a scheduled II controlled substance. Naloxegol was recently approved for the treatment of opioid-induced constipation and is part of a class of medications known as PAMORAs (Peripherally Acting Mu Opioid Receptor Antagonists). Other FDA agents in this category include alvimopan (Entereg) and methylnaltrexone (Relistor).

The DEA’s decision to schedule naloxegol in any category is disillusioned at best, and in the authors’ opinion, more likely a knee-jerk reaction to the recent high scrutiny attributable to the purported “opioid epidemic.” By comparison, consider that naloxone is a legend but non-scheduled drug and dextromethorphan is an over-the-counter non-scheduled drug—both are dehydroxylated phenanthrenes. Also consider that more and more states are allowing naloxone in various packaging to be dispensed without a prescription and that naloxegol is a PEGylated form of naloxone.

But perhaps most telling is that noroxymorphone has no analgesic or euphoric activity by the oral or IV routes, although admittedly does have agonist activity by intrathecal administration according to animal studies

The Intrathecal route is the SPINAL FLUID in the spinal column… anything injected into this fluid MUST BE both sterile and preservative free.. otherwise there is at least the risk of spinal meningitis…. resulting in paralysis and maybe death. How many addicts are going to be able to develop the technique and adequate equipment to be able to inject into a spinal column ?

Don’t tell anyone at the DEA… but.. it is reported that some people have gotten “high” inhaling the gas/propellant from Readi-Wip Cream cans..

 

Filed under: General Problems